Login / Signup

Real-World Outcomes of Intravitreal Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema in Türkiye: MARMASIA Study Group Report No. 1.

Uğur YaylaMehmet Orkun SevikVeysel Levent KarabasÖzlem ŞahinAbdullah ÖzkayaNursal Melda YenerelBanu AçıkalınFatih Bilgehan KaplanEcem Önder TokuçHatice Selen KanarIşıl Kutlutürk KaragözEce Başaran EmengenAyşe Demirciler SönmezAslan AykutDr Utku LimonErdinc BozkurtIşılay SaygınTuğba Aydoğan GezginaslanÖzlem Aydın ÖncüEsra Türkseven KumralNimet Yeşim ErçalıkErkan Çelik
Published in: Turkish journal of ophthalmology (2023)
This largest real-life study of DME from Türkiye demonstrated BCVA gains inferior to randomized controlled trials, mainly due to the lower number of IVI. However, with the lower baseline BCVA and higher IDI combination rates in our cohorts, these gains were relatively superior to other real-life study counterparts.
Keyphrases
  • vascular endothelial growth factor
  • randomized controlled trial
  • metabolic syndrome
  • skeletal muscle
  • study protocol
  • insulin resistance
  • smoking cessation
  • combination therapy
  • age related macular degeneration